Wangli Tech Secures China's First Mobile-Based Digital Therapeutic Registration Certificate for Cognitive Impairment Treatment

January 18, 2022, Wangli TechnologyMobile-based"Cognitive Impairment Treatment Software“Approved for Medical Device Registration Certificate! This product is a mobile digital health product in the field of psychiatric/neurological treatment in China.”First Registration Certificate。

Wangli Technology's digital therapeutics product is the first in ChinaThe First in the Field of Psychiatry/NeurologyApproved by Medical Regulatory AuthoritiesMobile App. This software is designed forTreatment of Cognitive Impairment, providing algorithm-based intelligent cognitive remediation training, with dynamic adjustments to training and treatment protocols based on the patient’s therapeutic progress. Unlike existing software for treating cognitive impairments, this product is built on mobile internet technology, offering location-independent accessibility and ease of use, and has undergone rigorous approval by medical regulatory authorities. After users download it,Professional training can be accessed anytime, anywhere via mobile phone., thereby improving and enhancing cognitive function.

Among the multiple prescription digital therapeutics products approved by the U.S. FDA,Psychiatry Digital Therapeutics Products Have the Highest Number of Approvals, covering multiple areas such as substance abuse, depression, insomnia, and post-traumatic stress disorder. From the perspective of scientific principles, psychiatry is also the most suitable field for the clinical application of digital therapeutics.

China’s market boasts advantages such as a larger population base and more robust infrastructure than any other market globally, providing the most fertile ground for digital therapeutics based on mobile smart devices. The intervention and treatment model combining “mobile internet + psychiatry” offers patients a safer, more private, time-saving, and efficient way to access medical care, addressing issues of stigma and high costs associated with seeking treatment across different regions, while significantly enhancing the convenience of services.

“Cognitive Impairment” refers to cognitive deficits in memory, language, visuospatial ability, executive function, calculation, and comprehension/judgment caused by various conditions such as Alzheimer’s disease, depression, and stroke. These deficits result in impairments in language, perception, memory, executive function, and thinking, making it one of the most prevalent disorders in the psychiatric and neurological fields.

Effective treatment and management of cognitive impairment can significantly slow disease progression, enhance therapeutic outcomes, and improve patients' quality of life.

Wangli Technology has obtained regulatory approval, pioneering the field of digital therapeutics in psychiatry and neurology. It provides patients with cognitive impairments access to internationally leading psychiatric and neurological treatment modalities, offering more effective solutions for their treatment and rehabilitation.

The company has also accumulated a wealth of solutions for mental and psychological issues across various industries and severity levels, with the aim of contributing greater social value.